Raji TK+ Cells

The Raji TK+ cell line is a derivative of the Raji cell line, originally established from a Burkitt's lymphoma patient. It is distinguished by its expression of thymidine kinase (TK+), an enzyme critical for nucleotide salvage pathways and DNA synthesis. The Raji TK+ variant is utilized in research areas focusing on cell cycle dynamics, DNA replication, and targeted gene editing techniques. The expression of TK+ makes this cell line a robust model for studying the effects of nucleoside analogs and other TK-dependent therapeutic agents. As a lymphoblastoid cell line, Raji TK+ retains the morphological and immunophenotypic characteristics of its parent line, including high nuclear-cytoplasmic ratio and surface markers typical of B cells, such as CD19 and CD20. It is permissive for Epstein-Barr virus (EBV) studies, which is a hallmark of the Raji lineage, allowing exploration of EBV-related oncogenesis and immune evasion mechanisms. The cell line's genomic stability and reproducibility across experiments further enhance its utility in fundamental and translational research. Burkitt Lymphoma cell lines, Jaw bone, Burkitt lymphoma, Growth Conditions: Suspension, Biosafety level: BSL 1